Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences    GILD

GILEAD SCIENCES (GILD)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Gilead Sciences : and Kite Pharma Announce Expiration of Hart-Scott-Rodino Waiting Period

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/05/2017 | 10:25pm CEST

By a News Reporter-Staff News Editor at Pharma Business Week -- Gilead Sciences, Inc. (Nasdaq: GILD) and Kite Pharma, Inc. (Nasdaq: KITE) announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) with respect to Gilead's cash tender offer for Kite expired at 11:59 p.m. on September 25, 2017 (see also Biotechnology Companies).

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170926005682/en/

On September 8, 2017, Gilead and Kite filed the Premerger Notification and Report Forms required under the HSR Act with the Federal Trade Commission and the Antitrust Division of the U.S. Department of Justice.

Keywords for this news article include: Gilead Sciences Inc., Biotechnology Companies, Biopharmaceutical Companies.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

(c) 2017 NewsRx LLC, source Health Newsletters

Stocks mentioned in the article
ChangeLast1st jan.
KITE PHARMA INC 0.00%-End-of-day quote.300.96%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GILEAD SCIENCES
04/23ASTELLAS PHARMA : Announces Sale of Certain Agensys Research Facilities to Kite,..
AQ
04/23GILEAD SCIENCES : to Release First Quarter 2018 Financial Results on Tuesday, Ma..
AQ
04/21ASTELLAS PHARMA : sells certain U.S. research facilities to Gilead
AQ
04/20GILEAD SCIENCES : Non-profit KEI sues NIH to block Gilead's anti-CD30 CAR T pate..
AQ
04/19GILEAD SCIENCES : Research Conducted at Gilead Sciences Inc. Has Provided New In..
AQ
04/19GILEAD SCIENCES : New Hepatitis C Virus Data Have Been Reported by Investigators..
AQ
04/19GILEAD SCIENCES : Study Results from Gilead Sciences Broaden Understanding of HI..
AQ
04/19GILEAD SCIENCES : Tmunity tops off series A round
AQ
04/19GILEAD SCIENCES : Astellas Announces Sale of Certain Agensys Research Facilities..
PR
04/17GILEAD SCIENCES : to Release First Quarter 2018 Financial Results on Tuesday, Ma..
BU
More news
News from SeekingAlpha
02:28pBY THE NUMBERS : Healthcare Stocks With Big Cash Distributions 
01:42aJF'S CORE BIOTECH BUYS #12 : Updates And Introducing Our 18th Selection 
04/23The More It Drops, The More I Buy - Part 3 
04/23How To Retire At 65 With Only Half A Million 
04/23GILEAD : Will Medicare Boost Yescarta Sales? 
Financials ($)
Sales 2018 21 295 M
EBIT 2018 11 197 M
Net income 2018 6 715 M
Debt 2018 17 121 M
Yield 2018 3,06%
P/E ratio 2018 14,16
P/E ratio 2019 13,38
EV / Sales 2018 5,32x
EV / Sales 2019 5,45x
Capitalization 96 094 M
Chart GILEAD SCIENCES
Duration : Period :
Gilead Sciences Technical Analysis Chart | GILD | US3755581036 | 4-Traders
Technical analysis trends GILEAD SCIENCES
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 89,0 $
Spread / Average Target 20%
EPS Revisions
Managers
NameTitle
John F. Milligan President, Chief Executive Officer & Director
John C. Martin Chairman
Robin L. Washington CFO, Principal Accounting Officer & Executive VP
Norbert W. Bischofberger CSO, Executive VP-Research & Development
George Pratt Shultz Director-Emeritus
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES2.88%96 094
VERTEX PHARMACEUTICALS5.53%40 153
REGENERON PHARMACEUTICALS-16.41%33 844
GENMAB23.13%12 797
BEIGENE LTD (ADR)71.91%8 998
BLUEBIRD BIO INC-5.53%8 522